Ixempra (Ixabepilone) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 27, 2012

Ixempra

Breast Cancer »

Breast cancer facts

Breast cancer is the most common cancer among American women.
One in every eight women in the United States develops breast cancer.
There are many types of breast cancer that differ in their capability of spreading (metastasize) to other body tissues.
The causes of breast cancer are not yet fully known although a number of risk factors have been identified.
There are many different types of breast cancer.
Breast cancer is diagnosed with physician and self-examination of the breasts, mammography, ultrasound testing, and biopsy.
Treatment of breast cancer depends on the type of cancer and its stage (the extent of spread in the body).

According to the American Cancer society:

Over 200,000 new cases of invasive breast cancer are diagnosed each year.
Nearly 40,000 women will die of breast cancer in 2011.
There are over 2...

Read the Breast Cancer article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Ixempra User Reviews >>

Ixempra

Breast Cancer Slideshow Pictures

Take the Breast Cancer Quiz

Disease Prevention in Women Slideshow Pictures

font size

OVERDOSE

Experience with overdose of IXEMPRA is limited to isolated cases. The adverse reactions reported in these cases included peripheral neuropathy, fatigue, musculoskeletal pain/myalgia, and gastrointestinal symptoms (nausea, anorexia, diarrhea, abdominal pain, stomatitis). The highest dose mistakenly received was 100 mg/m² (total dose 185 mg).

There is no known antidote for overdosage of IXEMPRA. In case of overdosage, the patient should be closely monitored and supportive treatment should be administered.

Management of overdose should include supportive medical interventions to treat the presenting clinical manifestations.

CONTRAINDICATIONS

IXEMPRA is contraindicated in patients with a history of a severe (CTC grade 3/4) hypersensitivity reaction to agents containing Cremophor® EL or its derivatives (eg, polyoxyethylated castor oil) [see WARNINGS AND PRECAUTIONS].

IXEMPRA is contraindicated in patients who have a neutrophil count < 1500 cells/mm³ or a platelet count < 100,000 cells/mm³ [see WARNINGS AND PRECAUTIONS].

IXEMPRA in combination with capecitabine is contraindicated in patients with AST or ALT > 2.5 x ULN or bilirubin > 1 x ULN [see BOXED WARNING and WARNINGS AND PRECAUTIONS].

Last reviewed on RxList: 10/27/2011
This monograph has been modified to include the generic and brand name in many instances.